REGENXBIO (RGNX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.43
- Estimate
- -$0.11
- Surprise
- +499.2%
- Revenue (period 2026-06-30)
- $108.0M
- Score today
- 5.1/10
Revenue source: xbrl.
How the report landed
REGENXBIO (RGNX) beat the -$0.11 estimate with adjusted EPS of $0.43 — a large 499.2% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates RGNX Sell at 5.1/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +499.2% surprise compares with a +107.4% four-quarter average. Next scheduled report: 2027-03-04.
What argues against it
- Concentration risk — Pipeline: lead product candidates
- Quality below floor (2.2 < 4.0)
- Momentum score 2.5/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $7.16
- Price target
- $18.62
- Stop
- $6.66
- Upside to target
- +160.1%
- Reward-to-risk
- 10.7:1
Model outputs from TrendMatrix’s engine as of 2026-11-22 — shown for context, not personalized investment advice.
RGNX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $473.4M
- P/E (fwd)
- -2.3
- 52-week range
- $5.46–$16.19
- Off 52-week high
- 55.8%
- RSI (14)
- 50
- Volume vs avg
- 0.88×
- Score today
- 5.1/10